Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB571 in Advanced Solid Tumors
NCT06725381Phase 1Recruiting
- Sponsor
- Kelun-Biotech
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SKB571 in solid tumor, sponsored by Kelun-Biotech. Primary endpoint: Dose-limiting toxicity at 21 days. Started Dec 2024; status: recruiting.
02
Drugs
SKB571
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06725381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06725381.